Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Pharnext

    MCap

    EUR1m

    Last close

    EUR0.10

    ▲ 0.03 (42.86%)

    MGI – Media and Games Invest

    MCap

    EUR235m

    Last close

    EUR1.50

    ▲ 0.35 (30.21%)

    Checkit

    MCap

    GBP26m

    Last close

    GBP0.24

    ▲ 3.00 (14.29%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Basilea Pharmaceutica (SIX: BSLN)

Last close As at 15/04/2024

CHF40.70

▲ 0.25 (0.62%)

Market capitalisation

CHF534m

Basilea Pharmaceutica is focused on treating infectious diseases; marketed products are Cresemba (antifungal) and Zevtera (anti-MRSA broad-spectrum antibiotic). In late 2023, it expanded its pipeline to include BAL2062 (antifungal), tonabacase (antibiotic) and Phase III-ready fosmanogepix (antifungal).

There is an ever-increasing need for therapeutic agents that are efficacious against drug-resistant strains of bacteria (eg MRSA) or fungi. Hence the opportunities for Zevtera and Cresemba could be significant.

Latest Insights

View More

Healthcare | Flash note

Basilea Pharmaceutica — CARB-X grant for preclinical programs

Healthcare | Update

Basilea Pharmaceutica — Zevtera crosses key US regulatory hurdle

Healthcare | Flash note

Basilea Pharmaceutica — Strong Cresemba traction triggers milestone payment

Healthcare | edison tv

Interview with David Veitch, CEO of Basilea Pharmaceutica
misael-moreno-fN6K30xtiKE-unsplash-Basilea
Visit Website

Sector

Healthcare

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Nidhi Singh

Nidhi Singh

Analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Arron Aatkar

Associate analyst

Key Management

  • Adesh Kaul

    CFO

  • David Veitch

    CEO

  • Dung Tran

    Investor relations coordinator

Balance Sheet

Forecast net debt (CHFm)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 14.3 17.5 (12.6)
Relative 17.1 15.5 (13.0)
52 week high/low CHF48.6/CHF32.2

Financials

In the lead up to its capital markets day, Basilea Pharmaceutica announced it has received initial funding of up to US$0.9m through a grant from Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a global non-profit partnership backed by governments and foundations, for its preclinical antibiotics program. CARB-X is focused on supporting early-stage antibacterial research and development, and this grant is expected to support development work up until clinical candidate nomination in H224, with potential additional funding subject to achieving certain milestones. 2024 is shaping up to be an active year for Basilea, following the recent FDA approval and anticipated subsequent commercial launch of Zevtera in the US, as well as the initiation of Phase III studies for newly acquired antifungal asset Fosmanogepix (mid-2024).

Y/E Dec Revenue (CHFm) EBITDA (CHFm) PBT (CHFm) EPS (CHFc) P/E (x) P/CF (x)
2022A 147.8 19.6 12.3 104.10 39.1 N/A
2023A 157.6 20.8 10.8 89.66 45.4 N/A
2024E 187.2 34.0 28.0 233.65 17.4 N/A
2025E 209.1 37.9 32.3 269.24 15.1 N/A

Research

Update

Healthcare

Basilea Pharmaceutica — Zevtera crosses key US regulatory hurdle

Flash note

Healthcare

Basilea Pharmaceutica — Strong Cresemba traction triggers milestone payment

Healthcare

Flash note

Basilea Pharmaceutica — CARB-X grant for preclinical programs
View All

Further insights

insight

Healthcare

Antibiotic resistance

insight

Healthcare

Antibiotics

Analyst of the week

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

sromanoff@edisongroup.com 020 3077 5700
Read latest

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free